89 related articles for article (PubMed ID: 1948834)
21. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
[TBL] [Abstract][Full Text] [Related]
22. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
23. [Estradiol and estriol in the treatment of climacteric symptoms. A controlled trial].
Bennedsen H; Nielsen JV
Ugeskr Laeger; 1979 May; 141(22):1471-7. PubMed ID: 377743
[TBL] [Abstract][Full Text] [Related]
24. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
[TBL] [Abstract][Full Text] [Related]
25. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
26. Short-term effect of transdermal estrogen on autonomic nervous modulation in postmenopausal women.
Chao HT; Kuo CD; Su YJ; Chuang SS; Fang YJ; Ho LT
Fertil Steril; 2005 Nov; 84(5):1477-83. PubMed ID: 16275247
[TBL] [Abstract][Full Text] [Related]
27. [Subdermal implantation of estradiol 17 beta (25 mg) in hysterectomized and ovariectomized women. Effects of increased serum estradiol level and neurovegetative climacteric complaints].
Tsvetkov Ts; Tsvetkov K; Petkova U
Akush Ginekol (Sofiia); 2001; 41 Suppl 4():11-2. PubMed ID: 11519312
[No Abstract] [Full Text] [Related]
28. [A transdermal therapeutic system for hormonal therapy of climacteric deficiency pictures. A multicenter study].
Kerzel C; Keller PJ
Geburtshilfe Frauenheilkd; 1987 Aug; 47(8):565-8. PubMed ID: 3653671
[TBL] [Abstract][Full Text] [Related]
29. [One-year follow-up of women treated with transdermal administration of estrogen for post-castration and climacteric syndromes].
Rotta L; Matĕchová E
Cesk Gynekol; 1992 Dec; 57(9-10):479-88. PubMed ID: 1291124
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
Leodolter S; Sainz H; Moll-Schüler I; Mach R
Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
[TBL] [Abstract][Full Text] [Related]
31. Menopausal hot flushes: a double blind comparison of placebo, ethinyl oestradiol and norgestrel.
Dennerstein L; Burrows GD; Hyman G; Wood C
Br J Obstet Gynaecol; 1978 Nov; 85(11):852-6. PubMed ID: 363136
[TBL] [Abstract][Full Text] [Related]
32. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study.
Wiklund I; Karlberg J; Mattsson LA
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):824-30. PubMed ID: 8456888
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
35. Climacteric symptoms after oral and percutaneous hormone replacement therapy.
Jensen PB; Jensen J; Riis BJ; Rødbro P; Strøm V; Christiansen C
Maturitas; 1987 Nov; 9(3):207-15. PubMed ID: 2963205
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of Menorest in two positive-controlled studies.
Pornel B
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
[TBL] [Abstract][Full Text] [Related]
37. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial.
Jensen J; Christiansen C
Maturitas; 1983 Aug; 5(2):125-33. PubMed ID: 6415364
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms.
Chung TK; Yip SK; Lam P; Chang AM; Haines CJ
Maturitas; 1996 Oct; 25(2):115-23. PubMed ID: 8905602
[TBL] [Abstract][Full Text] [Related]
39. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression.
Saletu B; Brandstätter N; Metka M; Stamenkovic M; Anderer P; Semlitsch HV; Heytmanek G; Huber J; Grünberger J; Linzmayer L
Psychopharmacology (Berl); 1995 Dec; 122(4):321-9. PubMed ID: 8657828
[TBL] [Abstract][Full Text] [Related]
40. Lack of effects of transdermal estradiol on diastolic function: a randomized placebo-controlled double-blind short-term trial.
Fisman EZ; Tenenbaum A; Shapira I; Motro M; Pines A
Climacteric; 1999 Sep; 2(3):174-80. PubMed ID: 11910594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
